



DPC: 24/30497407 DC

BSI Group Headquarters

389 Chiswick High Road London W4 4AL

Tel: +44 (0)20 8996 9000

Fax: +44 (0)20 8996 7400

www.bsigroup.com

Date: 17 July 2024

Origin: International

Latest date for receipt of comments: 12 August 2024

Project No. 2023/00137

Responsible committee: CH/172/7 Eye implants

Interested committees:

Title: Draft BS EN ISO 16671 Ophthalmic implants — Irrigating solutions for ophthalmic surgery.

Please notify admin.start@bsigroup.com if you are aware of any keywords that might assist in clarifying or identifying the standard or of the content of this standard:

- i) has any issues related to 3rd party IPR, patent or copyright
- ii) affects other national standard(s)
- iii) requires additional national guidance or information

WARNING: THIS IS A DRAFT AND MUST NOT BE REGARDED OR USED AS A BRITISH STANDARD. THIS DRAFT IS NOT CURRENT BEYOND 12 August 2024

This draft is issued to allow comments from interested parties; all comments will be given consideration prior to publication. No acknowledgement will normally be sent. **See overleaf for information on the submission of comments.**

No copying is allowed, in any form, without prior written permission from BSI except as permitted under the Copyright, Designs and Patent Act 1988 or for circulation within a nominating organization for briefing purposes. Electronic circulation is limited to dissemination by e-mail within such an organization by committee members.

Further copies of this draft may be purchased from BSI Shop <http://shop.bsigroup.com> or from BSI Customer Services, Tel: +44(0) 20 8996 9001 or email cservices@bsigroup.com. British, International and foreign standards are also available from BSI Customer Services.

Information on the co-operating organizations represented on the committees referenced above may be obtained from <https://standardsdevelopment.bsigroup.com/>.

E-mail: admin.start@bsigroup.com

Introduction

This draft standard is based on national and international discussions. Your comments on this draft are invited and will assist in the preparation of the consequent standard.

For international standards, comments will be reviewed by the relevant UK national committee before sending the consensus UK vote and comments to the international committee, which will then decide appropriate action. If the international standard is approved, it is usual for the text to be published as a British Standard.

For national standards, comments will be reviewed by the relevant UK national committee and the resulting standards published as a British Standard.

UK Vote

Please indicate whether you consider the UK should submit a negative (with supporting technical reasons) or positive vote on this draft. Please indicate if you are aware of any reason why this draft standard should not be published as a British Standard.

Submission of Comments

- **Annotated drafts are not acceptable and will be rejected.**
- All comments should be submitted online at <https://standardsdevelopment.bsigroup.com/>. You will need to register in order to comment.

Template for comments and secretariat observations

Date: xx/xx/20xx	Document: ISO/DIS xxxx
------------------	------------------------

1	2	(3)	4	5	(6)	7
MB	Clause No./ Subclause No./Annex (e.g. 3.1)	Paragraph/ Figure/Table/Note	Type of comment	Comment (justification for change) by the MB	Proposed change by the MB	Secretariat observations on each comment submitted
	3.1	Definition 1	ed	Definition is ambiguous and needs clarifying.	Amend to read '...so that the mains connector to which no connection...'	
	6.4	Paragraph 2	te	The use of the UV photometer as an alternative cannot be supported as serious problems have been encountered in its use in the UK.	Delete reference to UV photometer.	



DRAFT International Standard

ISO/DIS 16671.2

Ophthalmic implants — Irrigating solutions for ophthalmic surgery

*Implants ophtalmiques — Solutions d'irrigation pour la chirurgie
ophtalmique*

ICS: 11.040.70

ISO/TC 172/SC 7

Secretariat: **DIN**

Voting begins on:
2024-07-17

Voting terminates on:
2024-09-11

This document is circulated as received from the committee secretariat.

ISO/CEN PARALLEL PROCESSING

Reference number
ISO/DIS 16671.2:2024(en)

Full document details: 24/30497407 DC

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENTS AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

© ISO 2024  **Documents**
Document Sharing Hub



COPYRIGHT PROTECTED DOCUMENT

© ISO 2024

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword	iv
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Intended performance	2
5 Design attributes	2
5.1 General	2
5.2 Chemical description and contaminants	3
5.3 Water used	3
5.4 Characterization of the finished product	3
5.4.1 General	3
5.4.2 pH and buffering capacity	3
5.4.3 Osmolality	4
5.4.4 Spectral transmittance	4
5.4.5 Particulates	4
6 Design evaluation	5
6.1 General	5
6.2 Evaluation of biological safety	5
6.2.1 General	5
6.2.2 Bacterial endotoxins test	5
6.2.3 Intraocular irritation and inflammation	5
6.3 Clinical evaluation	6
7 Sterilization	6
8 Product stability	6
9 Packaging	7
9.1 Protection from damage during storage and transport	7
9.2 Maintenance of sterility in transit and storage	7
10 Information supplied by the manufacturer	7
Annex A (informative) Example of a suitable method for pH measurement and buffer capacity determination	9
Annex B (normative) Particulate contamination: visible particulates	10
Annex C (normative) Light obscuration test method for particulate contamination: sub-visible particles	11
Annex D (normative) Microscopic test method for particulate contamination: sub-visible particles	13
Annex E (normative) Intraocular irrigation test	17
Annex F (normative) Clinical investigation	19
Annex G (informative) Analyses of OIS clinical data	21
Annex H (informative) Sample size calculation	23
Bibliography	25

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 172, *Optics and photonics*, Subcommittee SC 7, *Ophthalmic optics and instruments*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 170, *Ophthalmic optics*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This third edition cancels and replaces the second edition (ISO 16671:2015), which has been technically revised

The main changes are as follows:

- Inclusion of applicable sections from ISO 14630 throughout the document and removal of any reference to that standard. It was further clarified that ophthalmic irrigation solutions (OIS) are not implants by their intended use but are likely to share some of the risks related to non-active implants. Therefore, the following clauses and subclauses have been revised: [Clause 4](#), [Clause 5](#), [Clause 7](#) and [9.1](#);
- Clarifications of terms [3.1](#), [3.2](#), [3.3](#) and [3.4](#);
- Revised [5.1](#) for a more accurate description of design attributes;
- Revised [Clause 7](#) to clarify the risks associated with components of OIS sterilized by ethylene oxide (EO);
- Revised [Clause 8](#) to clarify that the real time shelf-life testing shall be performed and the accelerated shelf-life testing is optional;
- Revised [Annex E](#) to provide additional clarification regarding the number of test and control eyes enrolled in the study and that use of medication during the study that could possibly impact the study results;
- [Annex F](#) was changed from informative to normative and clarified that the same intraocular surgical procedure is performed in the test and control arms and changed the first post-operative intraocular pressure (IOP) measurement from 6 h ± 2 h to 8 h ± 2 h to capture the effect of irrigation solution on IOP and align it with Clause F.2 of ISO 15798 standard;
- Inclusion of [Annex G](#);

ISO/DIS 16671.2:2024(en)

- The example for patient number calculation is incorporated into [Annex H](#) (informative);
- Corrected [Formulae H.1](#) and [H.2](#).

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Ophthalmic implants — Irrigating solutions for ophthalmic surgery

1 Scope

This document defines requirements with regards to safety for the intended performance, design attributes, preclinical and clinical evaluation, sterilization, product packaging, product labelling, and the information supplied by the manufacturer.

This document applies to ophthalmic irrigating solutions (OIS), used during ophthalmic surgery. These solutions do not provide any primary immunological, pharmacological, or metabolic function.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 13408-1, *Aseptic processing of health care products — Part 1: General requirements*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14971, *Medical devices — Application of risk management to medical devices*

ISO 15223-1, *Medical devices — Symbols to be used with information to be supplied by the manufacturer — Part 1: General requirements*

ISO 20417, *Medical devices — Information to be supplied by the manufacturer*

ISO 22442-1, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*

ISO 22442-2, *Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling*

ISO 22442-3, *Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents*

European Pharmacopeia (Ph. Eur) 0169 *Water for injections*

United States Pharmacopeia (USP) 1231> *Water for pharmaceutical purposes*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1 ophthalmic irrigating solution

OIS

aqueous solution that is used to physiologically stabilize the ocular tissue

Note 1 to entry: It does not provide any primary immunological, pharmacological, or metabolic function.

3.2 primary container

container that is in direct contact with the product

3.3 sterile barrier system

minimum package that prevents ingress of microorganisms and allows aseptic presentation of the product at the point of use

[SOURCE: ISO11139: 2018, 3.272^[2]]

Note 1 to entry: for additional details regarding sterile barrier system see ISO 11607-1

3.4 storage container

part of the packaging intended to protect the device during transport and storage, containing the sterile barrier system

4 Intended performance

This document describes OIS as non-solid medical devices that are physiologically and functionally compatible with the ocular tissues and are used to rinse the surface of the eye, stabilize the ocular surface, and/or manipulate intraocular tissues, spaces, and structures by physiological means.

The manufacturer shall describe and document the functional characteristics of the OIS in terms of its chemical composition and physical properties, the intended surgical applications, the conditions of use and effects upon ocular tissues, with particular regard to safety.

The intended performance shall be determined taking into account published standards, published clinical and scientific literature, validated test results, pre-clinical and clinical evaluation, and clinical investigations.

5 Design attributes

5.1 General

The following subclauses list specific design attributes to be met for the intended performance. Tests described therein are intended to apply when qualifying materials, but not necessarily apply as a routine quality assurance/control programme. A risk assessment shall be performed in accordance with ISO 14971. OIS design attributes shall be documented. Where any of the design attributes are not considered to be relevant, the reason for such shall be documented and justified.

All testing requirements specified below shall be performed with finished, sterilized product, ready for release. Any analytical methods utilized shall be validated.